ARCOSA INC (ACA) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:ACA • US0396531008

117.87 USD
+1.49 (+1.28%)
At close: Feb 3, 2026
117.87 USD
0 (0%)
After Hours: 2/3/2026, 8:04:00 PM
Fundamental Rating

5

Overall ACA gets a fundamental rating of 5 out of 10. We evaluated ACA against 55 industry peers in the Construction & Engineering industry. Both the profitability and the financial health of ACA get a neutral evaluation. Nothing too spectacular is happening here. ACA has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • ACA had positive earnings in the past year.
  • ACA had a positive operating cash flow in the past year.
  • In the past 5 years ACA has always been profitable.
  • ACA had a positive operating cash flow in each of the past 5 years.
ACA Yearly Net Income VS EBIT VS OCF VS FCFACA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

1.2 Ratios

  • ACA has a Return On Assets (2.94%) which is in line with its industry peers.
  • ACA has a Return On Equity (5.75%) which is in line with its industry peers.
  • ACA has a Return On Invested Capital (4.99%) which is comparable to the rest of the industry.
  • The Average Return On Invested Capital over the past 3 years for ACA is significantly below the industry average of 15.97%.
  • The 3 year average ROIC (3.99%) for ACA is below the current ROIC(4.99%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.94%
ROE 5.75%
ROIC 4.99%
ROA(3y)4.56%
ROA(5y)3.97%
ROE(3y)7.3%
ROE(5y)6.21%
ROIC(3y)3.99%
ROIC(5y)4.04%
ACA Yearly ROA, ROE, ROICACA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2 4 6 8 10

1.3 Margins

  • ACA has a Profit Margin of 5.25%. This is in the better half of the industry: ACA outperforms 63.64% of its industry peers.
  • ACA's Profit Margin has declined in the last couple of years.
  • ACA has a Operating Margin of 10.27%. This is in the better half of the industry: ACA outperforms 72.73% of its industry peers.
  • ACA's Operating Margin has declined in the last couple of years.
  • The Gross Margin of ACA (21.61%) is better than 65.45% of its industry peers.
  • In the last couple of years the Gross Margin of ACA has remained more or less at the same level.
Industry RankSector Rank
OM 10.27%
PM (TTM) 5.25%
GM 21.61%
OM growth 3Y11.96%
OM growth 5Y-2.91%
PM growth 3Y2.37%
PM growth 5Y-10.81%
GM growth 3Y3.69%
GM growth 5Y0.93%
ACA Yearly Profit, Operating, Gross MarginsACA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

More info and screens

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ACA is destroying value.
  • The number of shares outstanding for ACA has been increased compared to 1 year ago.
  • Compared to 5 years ago, ACA has more shares outstanding
  • The debt/assets ratio for ACA is higher compared to a year ago.
ACA Yearly Shares OutstandingACA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ACA Yearly Total Debt VS Total AssetsACA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

  • An Altman-Z score of 2.55 indicates that ACA is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • ACA has a Altman-Z score of 2.55. This is comparable to the rest of the industry: ACA outperforms 45.45% of its industry peers.
  • ACA has a debt to FCF ratio of 5.03. This is a neutral value as ACA would need 5.03 years to pay back of all of its debts.
  • The Debt to FCF ratio of ACA (5.03) is better than 63.64% of its industry peers.
  • ACA has a Debt/Equity ratio of 0.61. This is a neutral value indicating ACA is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.61, ACA is in line with its industry, outperforming 58.18% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 5.03
Altman-Z 2.55
ROIC/WACC0.5
WACC9.97%
ACA Yearly LT Debt VS Equity VS FCFACA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.3 Liquidity

  • ACA has a Current Ratio of 2.02. This indicates that ACA is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of ACA (2.02) is better than 87.27% of its industry peers.
  • A Quick Ratio of 1.30 indicates that ACA should not have too much problems paying its short term obligations.
  • The Quick ratio of ACA (1.30) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 1.3
ACA Yearly Current Assets VS Current LiabilitesACA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 17.03% over the past year.
  • The Earnings Per Share has been growing slightly by 5.16% on average over the past years.
  • ACA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.96%.
  • The Revenue has been growing by 8.15% on average over the past years. This is quite good.
EPS 1Y (TTM)17.03%
EPS 3Y16.17%
EPS 5Y5.16%
EPS Q2Q%71.43%
Revenue 1Y (TTM)13.96%
Revenue growth 3Y8.06%
Revenue growth 5Y8.15%
Sales Q2Q%24.58%

3.2 Future

  • The Earnings Per Share is expected to grow by 22.53% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, ACA will show a small growth in Revenue. The Revenue will grow by 7.33% on average per year.
EPS Next Y42.05%
EPS Next 2Y27.53%
EPS Next 3Y22.53%
EPS Next 5YN/A
Revenue Next Year10.93%
Revenue Next 2Y8.42%
Revenue Next 3Y7.33%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ACA Yearly Revenue VS EstimatesACA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B
ACA Yearly EPS VS EstimatesACA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 31.18, ACA can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Earnings ratio of ACA indicates a somewhat cheap valuation: ACA is cheaper than 61.82% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of ACA to the average of the S&P500 Index (28.18), we can say ACA is valued inline with the index average.
  • The Price/Forward Earnings ratio is 24.08, which indicates a rather expensive current valuation of ACA.
  • Based on the Price/Forward Earnings ratio, ACA is valued a bit cheaper than 78.18% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 25.51, ACA is valued at the same level.
Industry RankSector Rank
PE 31.18
Fwd PE 24.08
ACA Price Earnings VS Forward Price EarningsACA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ACA is valued cheaper than 83.64% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, ACA is valued cheaply inside the industry as 83.64% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 18.38
EV/EBITDA 13.81
ACA Per share dataACA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ACA's earnings are expected to grow with 22.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.74
PEG (5Y)6.04
EPS Next 2Y27.53%
EPS Next 3Y22.53%

More info and screens

4

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.17%, ACA is not a good candidate for dividend investing.
  • ACA's Dividend Yield is a higher than the industry average which is at 0.14.
  • Compared to an average S&P500 Dividend Yield of 1.83, ACA's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.17%

5.2 History

  • The dividend of ACA decreases each year by -0.48%.
  • ACA has been paying a dividend for over 5 years, so it has already some track record.
  • ACA has not decreased its dividend in the past 5 years, so it has a somewhat stable track record.
Dividend Growth(5Y)-0.48%
Div Incr Years0
Div Non Decr Years5
ACA Yearly Dividends per shareACA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 2026 0.05 0.1 0.15

5.3 Sustainability

  • 6.66% of the earnings are spent on dividend by ACA. This is a low number and sustainable payout ratio.
DP6.66%
EPS Next 2Y27.53%
EPS Next 3Y22.53%
ACA Yearly Income VS Free CF VS DividendACA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
ACA Dividend Payout.ACA Dividend Payout, showing the Payout Ratio.ACA Dividend Payout.PayoutRetained Earnings

More info and screens

ARCOSA INC

NYSE:ACA (2/3/2026, 8:04:00 PM)

After market: 117.87 0 (0%)

117.87

+1.49 (+1.28%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryConstruction & Engineering
Earnings (Last)10-30
Earnings (Next)02-25
Inst Owners94.81%
Inst Owner Change-3.09%
Ins Owners1.8%
Ins Owner Change-1.18%
Market Cap5.78B
Revenue(TTM)2.83B
Net Income(TTM)148.60M
Analysts86
Price Target126.28 (7.13%)
Short Float %1.85%
Short Ratio4.11
Dividend
Industry RankSector Rank
Dividend Yield 0.17%
Yearly Dividend0.2
Dividend Growth(5Y)-0.48%
DP6.66%
Div Incr Years0
Div Non Decr Years5
Ex-Date01-15
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.63%
Min EPS beat(2)15.61%
Max EPS beat(2)17.65%
EPS beat(4)3
Avg EPS beat(4)38.79%
Min EPS beat(4)-40.32%
Max EPS beat(4)162.24%
EPS beat(8)7
Avg EPS beat(8)30.62%
EPS beat(12)11
Avg EPS beat(12)32.12%
EPS beat(16)15
Avg EPS beat(16)40.53%
Revenue beat(2)1
Avg Revenue beat(2)-1.27%
Min Revenue beat(2)-3.72%
Max Revenue beat(2)1.18%
Revenue beat(4)2
Avg Revenue beat(4)-1.29%
Min Revenue beat(4)-4.44%
Max Revenue beat(4)1.83%
Revenue beat(8)4
Avg Revenue beat(8)-0.83%
Revenue beat(12)7
Avg Revenue beat(12)0.53%
Revenue beat(16)11
Avg Revenue beat(16)1.99%
PT rev (1m)3.34%
PT rev (3m)6.72%
EPS NQ rev (1m)-0.56%
EPS NQ rev (3m)4.48%
EPS NY rev (1m)0.59%
EPS NY rev (3m)6.07%
Revenue NQ rev (1m)-0.16%
Revenue NQ rev (3m)-0.17%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)0.66%
Valuation
Industry RankSector Rank
PE 31.18
Fwd PE 24.08
P/S 2.04
P/FCF 18.38
P/OCF 12.32
P/B 2.24
P/tB 6.3
EV/EBITDA 13.81
EPS(TTM)3.78
EY3.21%
EPS(NY)4.9
Fwd EY4.15%
FCF(TTM)6.41
FCFY5.44%
OCF(TTM)9.57
OCFY8.12%
SpS57.76
BVpS52.7
TBVpS18.72
PEG (NY)0.74
PEG (5Y)6.04
Graham Number66.95
Profitability
Industry RankSector Rank
ROA 2.94%
ROE 5.75%
ROCE 6.5%
ROIC 4.99%
ROICexc 5.24%
ROICexgc 8.62%
OM 10.27%
PM (TTM) 5.25%
GM 21.61%
FCFM 11.11%
ROA(3y)4.56%
ROA(5y)3.97%
ROE(3y)7.3%
ROE(5y)6.21%
ROIC(3y)3.99%
ROIC(5y)4.04%
ROICexc(3y)4.17%
ROICexc(5y)4.21%
ROICexgc(3y)7.17%
ROICexgc(5y)7.33%
ROCE(3y)5.21%
ROCE(5y)5.27%
ROICexgc growth 3Y4.01%
ROICexgc growth 5Y-10.09%
ROICexc growth 3Y4.98%
ROICexc growth 5Y-11.63%
OM growth 3Y11.96%
OM growth 5Y-2.91%
PM growth 3Y2.37%
PM growth 5Y-10.81%
GM growth 3Y3.69%
GM growth 5Y0.93%
F-Score5
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 5.03
Debt/EBITDA 3.04
Cap/Depr 68.36%
Cap/Sales 5.46%
Interest Coverage 250
Cash Conversion 90.74%
Profit Quality 211.71%
Current Ratio 2.02
Quick Ratio 1.3
Altman-Z 2.55
F-Score5
WACC9.97%
ROIC/WACC0.5
Cap/Depr(3y)104.81%
Cap/Depr(5y)89.02%
Cap/Sales(3y)7.45%
Cap/Sales(5y)6.15%
Profit Quality(3y)128.08%
Profit Quality(5y)133.99%
High Growth Momentum
Growth
EPS 1Y (TTM)17.03%
EPS 3Y16.17%
EPS 5Y5.16%
EPS Q2Q%71.43%
EPS Next Y42.05%
EPS Next 2Y27.53%
EPS Next 3Y22.53%
EPS Next 5YN/A
Revenue 1Y (TTM)13.96%
Revenue growth 3Y8.06%
Revenue growth 5Y8.15%
Sales Q2Q%24.58%
Revenue Next Year10.93%
Revenue Next 2Y8.42%
Revenue Next 3Y7.33%
Revenue Next 5YN/A
EBIT growth 1Y48.65%
EBIT growth 3Y20.99%
EBIT growth 5Y5.01%
EBIT Next Year135.94%
EBIT Next 3Y39.06%
EBIT Next 5YN/A
FCF growth 1Y5015.62%
FCF growth 3Y56.55%
FCF growth 5Y2.7%
OCF growth 1Y146.35%
OCF growth 3Y44.47%
OCF growth 5Y6.95%

ARCOSA INC / ACA FAQ

Can you provide the ChartMill fundamental rating for ARCOSA INC?

ChartMill assigns a fundamental rating of 5 / 10 to ACA.


Can you provide the valuation status for ARCOSA INC?

ChartMill assigns a valuation rating of 6 / 10 to ARCOSA INC (ACA). This can be considered as Fairly Valued.


How profitable is ARCOSA INC (ACA) stock?

ARCOSA INC (ACA) has a profitability rating of 5 / 10.


What is the valuation of ARCOSA INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ARCOSA INC (ACA) is 31.18 and the Price/Book (PB) ratio is 2.24.


How financially healthy is ARCOSA INC?

The financial health rating of ARCOSA INC (ACA) is 5 / 10.